Core Viewpoint - The approval of SYH9089 injection by the National Medical Products Administration of China marks a significant advancement for the company in the field of postoperative analgesia, addressing a critical clinical need for long-lasting pain relief solutions [1] Group 1: Product Development - The SYH9089 injection utilizes a mechanism that inhibits sodium ion channels in nerve cells, providing reversible blockage of impulse conduction along nerve fibers [1] - This product aims to reduce the frequency of administration, fulfilling the continuous pain relief requirements in postoperative settings and decreasing reliance on opioid medications [1] - The long-acting drug delivery technology platform allows for pain relief duration of up to one week with a single administration, potentially making it the first ultra-long-acting analgesic in China [1] Group 2: Clinical Research and Safety - Preclinical studies indicate that SYH9089 injection shows no systemic toxicity or new toxic organ targets, demonstrating significant long-lasting analgesic advantages compared to existing ropivacaine injections [1] - The approved clinical indication for this product is postoperative pain relief, highlighting its potential to meet urgent clinical demands in the ultra-long-acting postoperative analgesia market [1]
石药集团(01093)：罗哌卡因长效注射液(SYH9089注射液)在中国获临床试验批准